Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

BioCorRx stock price, quote, forecast and news

BICX
US09073C2052
A1XERB

Price

0.32
Today +/-
-0.14
Today %
-37.97 %
P

BioCorRx stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the BioCorRx stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the BioCorRx stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the BioCorRx stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze BioCorRx's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

BioCorRx Stock Price History

DateBioCorRx Price
8/8/20240.32 undefined
8/7/20240.47 undefined
8/6/20240.47 undefined
8/2/20240.53 undefined
7/31/20240.53 undefined
7/30/20240.53 undefined
7/29/20240.49 undefined
7/25/20240.52 undefined
7/24/20240.52 undefined
7/17/20240.52 undefined
7/16/20240.52 undefined

BioCorRx Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into BioCorRx, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by BioCorRx from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects BioCorRx’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of BioCorRx. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into BioCorRx’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing BioCorRx’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on BioCorRx’s growth potential.

BioCorRx Revenue, EBIT and net profit per share

DateBioCorRx RevenueBioCorRx EBITBioCorRx Net Income
2025e2.51 M undefined0 undefined-6.83 M undefined
2024e1 M undefined0 undefined-5.9 M undefined
202389,160 undefined-3.74 M undefined-3.77 M undefined
2022210,000 undefined-4.7 M undefined-4.37 M undefined
202150,000 undefined-5.37 M undefined-5.28 M undefined
2020120,000 undefined-7.49 M undefined-3.47 M undefined
2019240,000 undefined-5.56 M undefined-6.04 M undefined
2018380,000 undefined-4.38 M undefined-6.51 M undefined
2017660,000 undefined-2.89 M undefined-29.71 M undefined
2016700,000 undefined-2.18 M undefined-5.9 M undefined
2015920,000 undefined-5.12 M undefined-4.67 M undefined
20141.17 M undefined-3.05 M undefined-3.13 M undefined
2013710,000 undefined-2.51 M undefined-3.84 M undefined
2012870,000 undefined-620,000 undefined-890,000 undefined
2011770,000 undefined-340,000 undefined-410,000 undefined
2010140,000 undefined-150,000 undefined-150,000 undefined
20090 undefined-10,000 undefined-10,000 undefined
20080 undefined-10,000 undefined-10,000 undefined

BioCorRx Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20082009201020112012201320142015201620172018201920202021202220232024e2025e
000000100000000012
-----------------100.00
------------------
000000000000000000
00000-2-3-5-2-2-4-5-7-5-4-300
-------300.00-----------
00000-3-3-4-5-29-6-6-3-5-4-3-5-6
-------33.3325.00480.00-79.31--50.0066.67-20.00-25.0066.6720.00
0.024.290.370.511.061.171.391.551.72.332.513.525.386.497.28.3400
------------------
Details

Keystats

ⓘ

Revenue and Growth

The BioCorRx Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the BioCorRx is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2008200920102011201220132014201520162017201820192020202120222023
00.010.0100.010.110.050.220.090.010.282.650.590.090.070.07
0000.531.070.310.080.0300.030.010.190.230.060.170.08
0000000000000000
0000000000000000
000020508060101030210160808044.89
00.010.010.531.10.470.210.310.10.050.323.050.980.230.320.19
000101010100202040610620490350148.22
0000000000000000
00000400000000000
0003.973.973.843.711.080.280.250.250.240.190.060.060.01
0000000000000000
0000060160107010104040404044.52
0003.983.983.953.881.090.370.280.30.890.850.590.450.2
00.010.014.515.084.424.091.40.470.330.623.941.830.820.770.39
0040120100130170180200260203030303030.29
00.0104.084.335.538.719.7710.844.6849.5260.2160.5763.0966.2368.25
-0.01-0.02-0.21-0.71-1.6-5.44-8.56-13.23-19.13-48.84-55.18-61.22-64.69-69.97-74.34-78.1
0000000000000000
0000000000000000
-0.01-0.01-0.173.492.830.220.32-3.28-8.13-3.9-5.64-0.98-4.09-6.85-8.08-9.82
00.010.010.630.620.450.590.531.061.221.550.711.181.782.012.47
000000000001.41.421.532.032.3
000.010.21.120.81.131.480.920.240.210.130.130.030.030.05
000.080.190.250.120.211.750.470.194.360.310.311.011.291.61
000000000000203000
00.010.11.021.991.371.933.762.451.656.122.553.064.385.366.43
000.09000.60.450.010.692.02000.090.170.070.07
0000000000000000
00000.262.241.390.935.460.580.212.442.93.223.533.84
000.0900.262.841.840.946.152.60.212.442.993.393.63.91
00.010.191.022.254.213.774.78.64.256.334.996.057.778.9610.34
-0.0100.024.515.084.434.091.420.470.350.694.011.960.920.880.52
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of BioCorRx provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand BioCorRx's financial health and stability.

Assets

BioCorRx's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that BioCorRx must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of BioCorRx after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into BioCorRx's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (k)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200820092010201120122013201420152016201720182019202020212022
00000-3-3-4-5-29-6-6-3-5-4
000000000000000
000000000000000
000001,000000000000
0000022442743001
000000000000000
000000000000000
00000000-1-2-1-2-2-3-2
000000000000000
000000000000000
000000000000000
000000000000000
000000002100000
00000000001,0000001,000
000010002225032
000000000006020
000000000000000
000000000002-200
0-0.01-0.13-0.13-0.930.090.170.05-2.32-2.54-1.89-3.06-2.16-3.59-2.04
000000000000000

BioCorRx stock margins

The BioCorRx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioCorRx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioCorRx.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the BioCorRx's sales revenue. A higher gross margin percentage indicates that the BioCorRx retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the BioCorRx's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the BioCorRx's total revenue generated. When comparing the revenue margin year over year, investors can gauge the BioCorRx's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the BioCorRx. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the BioCorRx's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

BioCorRx Margin History

BioCorRx Gross marginBioCorRx Profit marginBioCorRx EBIT marginBioCorRx Profit margin
2025e59.63 %0 %-272.64 %
2024e59.63 %0 %-588.47 %
202359.63 %-4,194.49 %-4,224.89 %
202295.24 %-2,238.1 %-2,080.95 %
202180 %-10,740 %-10,560 %
202025 %-6,241.67 %-2,891.67 %
201966.67 %-2,316.67 %-2,516.67 %
201855.26 %-1,152.63 %-1,713.16 %
201750 %-437.88 %-4,501.51 %
201675.71 %-311.43 %-842.86 %
201583.7 %-556.52 %-507.61 %
201481.2 %-260.68 %-267.52 %
201377.46 %-353.52 %-540.85 %
201254.02 %-71.26 %-102.3 %
201148.05 %-44.16 %-53.25 %
2010-7.14 %-107.14 %-107.14 %
200959.63 %0 %0 %
200859.63 %0 %0 %

BioCorRx Stock Sales Revenue, EBIT, Earnings per Share

The BioCorRx earnings per share therefore indicates how much revenue BioCorRx has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue BioCorRx earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates BioCorRx's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of BioCorRx’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating BioCorRx's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

BioCorRx Revenue, EBIT and net profit per share

DateBioCorRx Sales per ShareBioCorRx EBIT per shareBioCorRx Earnings per Share
2025e0.26 undefined0 undefined-0.71 undefined
2024e0.1 undefined0 undefined-0.61 undefined
20230.01 undefined-0.45 undefined-0.45 undefined
20220.03 undefined-0.65 undefined-0.61 undefined
20210.01 undefined-0.83 undefined-0.81 undefined
20200.02 undefined-1.39 undefined-0.64 undefined
20190.07 undefined-1.58 undefined-1.72 undefined
20180.15 undefined-1.75 undefined-2.59 undefined
20170.28 undefined-1.24 undefined-12.75 undefined
20160.41 undefined-1.28 undefined-3.47 undefined
20150.59 undefined-3.3 undefined-3.01 undefined
20140.84 undefined-2.19 undefined-2.25 undefined
20130.61 undefined-2.15 undefined-3.28 undefined
20120.82 undefined-0.58 undefined-0.84 undefined
20111.51 undefined-0.67 undefined-0.8 undefined
20100.38 undefined-0.41 undefined-0.41 undefined
20090 undefined-0 undefined-0 undefined
20080 undefined-0.5 undefined-0.5 undefined

BioCorRx business model

The company BioCorRx Inc is a US-American company that was founded in 2008 and is headquartered in Anaheim, California. BioCorRx specializes in the development and marketing of innovative treatment methods for alcohol and drug dependency. The history of BioCorRx began with the introduction of its flagship product, the BioCorRx Recovery Program, which is based on a novel medical technology called Naltrexone/Buprenorphine Implant. Unlike traditional methods of treating alcohol and drug addiction, which typically rely on medication and psychotherapeutic support, the BioCorRx Recovery Program is an implantable, long-term treatment system that continuously delivers the active ingredient Naltrexone or Buprenorphine into the patient's body. The idea behind this is that the active ingredients prevent withdrawal symptoms and thereby reduce the risk of relapse. In recent years, BioCorRx has expanded its product portfolio and expanded its business activities to new segments in order to further drive the company's growth. This includes, for example, the field of telemedicine services, which allow BioCorRx to offer its treatment technology and medical services through online communication. Telemedicine services such as virtual patient consultation or online group therapy programs are particularly in demand in times of COVID-19. Another focus of BioCorRx is the management of medical personnel. Studies have shown that good patient care and counseling heavily influence the success of treatment. BioCorRx has now also developed its own platform that eases and improves the management, training, and monitoring of medical staff. BioCorRx also utilizes the concept of franchise systems to market its products and services. The franchise system offers medical professionals and organizations working in the field of addiction treatment the opportunity to open their own BioCorRx clinic and offer the company's products and services in their local market. Each clinic is advised and supported by BioCorRx and must adhere to certain standards and quality criteria. In the future, BioCorRx plans to further diversify its product offering and develop new technologies to improve treatment options for alcohol and drug dependents. An example of such a technology is medication based on Ibogaine. BioCorRx has already started initial research in this direction and is actively working on pre-clinical studies. Overall, BioCorRx is a company that primarily focuses on innovative technologies for the treatment of addiction. The company has experienced substantial growth in recent years by expanding its product range and customer base, and focusing on the areas of telemedicine, personnel management, and franchise systems. With its forward-thinking technologies and strong emphasis on quality and patient satisfaction, BioCorRx is expected to continue playing an important role in addiction treatment in the years to come. BioCorRx is one of the most popular companies on Eulerpool.com.

BioCorRx SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

BioCorRx Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

BioCorRx historical P/E ratio, EBIT, and P/S ratio.

BioCorRx shares outstanding

The number of shares was BioCorRx in 2023 — This indicates how many shares 8.344 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue BioCorRx earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates BioCorRx's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of BioCorRx’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating BioCorRx's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

BioCorRx Stock splits

In BioCorRx's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for BioCorRx.

BioCorRx latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20230 -0.1  (0 %)2023 Q3
1

BioCorRx list of shareholders

%
Name
Stocks
Change
Date
23.18 % BICX Holding Company, L.L.C.2,227,57503/25/2024
14.26 % Lucido Louis Charles1,370,849-158,1803/28/2024
14.00 % Galligan Joseph J1,345,538187,7873/28/2024
1.67 % Emry (Kent)160,2636,1983/25/2024
0.96 % Granier (Brady James)91,9772003/25/2024
0.84 % Felix (Lourdes)80,4105,5913/28/2024
0.52 % Ingargiola (Luisa)49,843253/25/2024
0.32 % Welch (Tomas Patrick)30,3834,5333/25/2024
0.21 % Murthy (Harsha)19,7445,5913/28/2024
1

BioCorRx Executives and Management Board

Mr. Brady Granier50
BioCorRx Director
Compensation 275,000
Ms. Lourdes Felix55
BioCorRx Chief Executive Officer, Chief Financial Officer, Director (since 2012)
Compensation 270,000
Mr. Thomas Welch51
BioCorRx Executive Vice President
Compensation 165,000
Mr. Joseph Galligan63
BioCorRx Independent Director
Compensation 126,500
Mr. Louis Lucido74
BioCorRx President, Director (since 2019)
Compensation 80,000
1
2

BioCorRx Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Societal CDMO Stock
Societal CDMO
SupplierCustomer0,480,33----
1

Most common questions regarding BioCorRx

What values and corporate philosophy does BioCorRx represent?

BioCorRx Inc represents a strong set of values and a dedicated corporate philosophy. The company is committed to providing innovative solutions in the field of substance use disorder treatment. BioCorRx focuses on developing safe and effective approaches to help individuals overcome addiction and reclaim their lives. With a patient-centric approach, the company aims to provide comprehensive programs that combine medication-assisted treatment with behavioral support. BioCorRx exemplifies integrity, compassion, and a commitment to improving the well-being of individuals struggling with addiction. Through their cutting-edge solutions, BioCorRx Inc strives to make a positive impact in the field of addiction treatment and contribute to the overall betterment of society.

In which countries and regions is BioCorRx primarily present?

BioCorRx Inc is primarily present in the United States. Recognized as a leader in substance use disorder treatment, BioCorRx operates its headquarters in Anaheim, California. With a focus on developing innovative solutions for addiction recovery, the company's presence spans the entire US territory. BioCorRx Inc is dedicated to helping individuals overcome addiction and promoting healthier lives.

What significant milestones has the company BioCorRx achieved?

BioCorRx Inc, a leading pharmaceutical company, has accomplished several significant milestones in recent years. One of their key achievements includes the development and commercialization of their flagship product, the BioCorRx Recovery Program, which offers a unique, non-addictive approach to treating substance abuse. The company has also made remarkable strides in expanding their distribution networks, forging partnerships with healthcare professionals, and achieving regulatory approvals for their innovative products. Moreover, BioCorRx Inc has consistently demonstrated a commitment to research and development, continually exploring new avenues for improving addiction treatment. These accomplishments highlight BioCorRx Inc's dedication to revolutionizing the field of substance abuse recovery.

What is the history and background of the company BioCorRx?

BioCorRx Inc is a pharmaceutical company specializing in innovative addiction treatment solutions. Established in 2008, BioCorRx is dedicated to developing effective medications and programs to support those struggling with alcohol and opioid dependencies. The company focuses on combining its proprietary medication, known as the BioCorRx® Recovery Program, with cognitive-behavioral therapy to enhance patient outcomes and reduce relapse rates. With a mission to improve the lives of individuals battling addiction, BioCorRx Inc strives to provide comprehensive and personalized treatment options. Through its commitment and innovative approach, BioCorRx Inc has positioned itself as a leading player in the addiction treatment industry.

Who are the main competitors of BioCorRx in the market?

The main competitors of BioCorRx Inc in the market include pharmaceutical companies, such as Pfizer Inc, Johnson & Johnson, and Novartis AG. Other competitors in the addiction treatment industry include Alkermes plc and Indivior Inc. These companies operate in the same market, offering various products and services for addiction treatment. BioCorRx Inc, a leader in medication-assisted treatment solutions, competes with these companies through its innovative treatment program, BioCorRx Recovery.

In which industries is BioCorRx primarily active?

BioCorRx Inc is primarily active in the healthcare and pharmaceutical industries.

What is the business model of BioCorRx?

The business model of BioCorRx Inc revolves around providing innovative solutions for the treatment of substance abuse and addiction. The company specializes in developing and commercializing behavioral healthcare products and services. BioCorRx Inc offers the BioCorRx Recovery Program, which combines medication-assisted treatment with counseling and peer support. This comprehensive approach aims to help individuals overcome substance abuse by addressing the underlying factors contributing to addiction and promoting long-term recovery. By integrating medical and behavioral components, BioCorRx Inc strives to provide effective solutions for patients seeking to break free from addiction.

What is the P/E ratio of BioCorRx 2024?

The BioCorRx P/E ratio is -0.45.

What is the P/S ratio of BioCorRx 2024?

The BioCorRx P/S ratio is 2.66.

What is the AlleAktien quality score of BioCorRx?

The AlleAktien quality score for BioCorRx is 5/10.

What is the revenue of BioCorRx 2024?

The expected BioCorRx revenue is 1 M USD.

How high is the profit of BioCorRx 2024?

The expected BioCorRx profit is -5.9 M USD.

What is the business model of BioCorRx

BioCorRx Inc is a leading biotechnology company that develops innovative health solutions for the treatment of addiction disorders. The company specializes in the development and sale of medications for the treatment of drug and alcohol addiction. The company has two different divisions: BioCorRx Pharmaceuticals and BioCorRx Health. BioCorRx Pharmaceuticals focuses on the research, development, and marketing of naltrexone micro-implants for use in alcohol and opioid addiction. These micro-implants are small, biocompatible pellets that are implanted under the skin to allow for continuous release of naltrexone, reducing withdrawal symptoms. BioCorRx Pharmaceuticals also holds a license for the development of buprenorphine implants for the treatment of opioid addiction. The second division, BioCorRx Health, offers a unique integrative health solution for the treatment of addiction disorders. This program includes a variety of services, including program guidance, phone support, online courses, nutritional counseling, exercise therapy, and acupuncture. The program is based on the BioCorRx Recovery Formula, a patented approach that is truly personalized to the patient and their needs. In addition, BioCorRx Inc offers a range of additional products that help reduce addictive behavior and enhance the success of the program. These include capsules for support during withdrawal, special supplements for patients with N-acetylcysteine deficiency, and enhanced vitamin and mineral supplements. BioCorRx Inc has established a strong presence in the US market and is expanding its global presence. The company has formed strategic partnerships with distribution partners to market its products and services worldwide. BioCorRx has also built excellent relationships with addiction researchers, medical professionals, and leading addiction treatment centers. The business model of BioCorRx Inc is based on two pillars: the marketing of patented medications for the treatment of addiction disorders and the sale of integrative health solutions. The company aims to offer a complete, integrated program for the treatment of addiction disorders, which includes both pharmacological treatments and supportive services. Due to the high demand for effective addiction treatments and the high demand for innovative solutions, BioCorRx Inc's business is promising. The company is well positioned to continue growing and dominate the addiction treatment market. The translation is as follows: BioCorRx Inc is a leading biotechnology company that develops innovative health solutions for the treatment of addiction disorders. The company specializes in developing and selling medications to treat drug and alcohol addiction. The company has two divisions: BioCorRx Pharmaceuticals and BioCorRx Health. BioCorRx Pharmaceuticals focuses on researching, developing, and marketing naltrexone micro-implants for alcohol and opioid addiction. These micro-implants are small, biocompatible pellets implanted under the skin to release naltrexone continuously and reduce withdrawal symptoms. BioCorRx Pharmaceuticals also holds a license to develop buprenorphine implants for opioid addiction. BioCorRx Health offers a unique integrative health solution for addiction treatment, including program guidance, phone support, online courses, nutrition counseling, exercise therapy, and acupuncture. The program is based on the BioCorRx Recovery Formula, a patented approach tailored to each patient's needs. Additionally, BioCorRx Inc provides products to reduce addictive behavior and enhance program success. These include withdrawal support capsules, special supplements for N-acetylcysteine deficiency, and improved vitamin and mineral supplements. With a strong presence in the US market and plans for global expansion, BioCorRx Inc has formed strategic partnerships to market its products and services worldwide. The company has also established relationships with addiction researchers, medical professionals, and leading addiction treatment centers. BioCorRx Inc's business model focuses on marketing patented addiction medications and selling integrative health solutions. The company strives to offer a comprehensive program that combines pharmaceutical treatments with supportive services. Given the high demand for effective addiction treatments and innovative solutions, BioCorRx Inc is well positioned for growth and market dominance in addiction treatment.

What is the BioCorRx dividend?

BioCorRx pays a dividend of 0 USD distributed over payouts per year.

How often does BioCorRx pay dividends?

The dividend cannot currently be calculated for BioCorRx or the company does not pay out a dividend.

What is the BioCorRx ISIN?

The ISIN of BioCorRx is US09073C2052.

What is the BioCorRx WKN?

The WKN of BioCorRx is A1XERB.

What is the BioCorRx ticker?

The ticker of BioCorRx is BICX.

How much dividend does BioCorRx pay?

Over the past 12 months, BioCorRx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BioCorRx is expected to pay a dividend of 0 USD.

What is the dividend yield of BioCorRx?

The current dividend yield of BioCorRx is .

When does BioCorRx pay dividends?

BioCorRx pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BioCorRx?

BioCorRx paid dividends every year for the past 0 years.

What is the dividend of BioCorRx?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BioCorRx located?

BioCorRx is assigned to the 'Health' sector.

Wann musste ich die Aktien von BioCorRx kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BioCorRx from 8/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/11/2024.

When did BioCorRx pay the last dividend?

The last dividend was paid out on 8/11/2024.

What was the dividend of BioCorRx in the year 2023?

In the year 2023, BioCorRx distributed 0 USD as dividends.

In which currency does BioCorRx pay out the dividend?

The dividends of BioCorRx are distributed in USD.

All fundamentals about BioCorRx

Our stock analysis for BioCorRx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioCorRx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.